GKOS vs LLY · rev $336.2M vs P/E 39, rev $22.97B
Glaukos Corp (GKOS) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Glaukos Corp (GKOS) is a medical devices company listed on NYSE.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported GKOS revenue for 2026-06-30 was $336.2M. Net income was -$38.2M. GKOS currently screens at market cap $7.63B.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
GKOS currently screens at market cap $7.63B. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the GKOS and LLY stock pages for the full models.
Not investment advice.